FDA advisory panel to consider approving fourth COVID-19 vaccine, this one from Maryland's Novavax
USA TodayJUL 2022
The Spin
Narrative A
Vaccine conspiracy theories tragically stigmatized mRNA jabs for millions of people in America. An "old school" protein-based jab, similar to the flu shot, could have more appeal to the unvaccinated. US officials bet the farm on mRNA products, and it's wise to offer consumers alternatives.
Narrative B
Novavax is a latecomer to the COVID vaccine landscape, and its early production fumbles were costly. The market is already well established by Pfizer and Moderna in the US, and whether its non-mRNA formula will be accepted by entrenched vaccine skeptics remains very much to be seen.
Metaculus Prediction
There's an 84% chance that the US, UK, or EU will authorize an Omicron-specific booster before 2023, according to the Metaculus prediction community.
